---
title: The Effect of Periarticular Multi-Drug Regimen on Pain After Partial Hip Replacement
nct_id: NCT01112436
overall_status: UNKNOWN
phase: PHASE4
sponsor: Chung-Ang University Hosptial, Chung-Ang University College of Medicine
study_type: INTERVENTIONAL
primary_condition: Femoral Neck Fracture
countries: South Korea
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT01112436.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT01112436"
ct_last_update_post_date: 2011-06-27
last_seen_at: "2026-05-12T07:20:52.285Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# The Effect of Periarticular Multi-Drug Regimen on Pain After Partial Hip Replacement

**Official Title:** The Effect of Periarticular Injection of Multi-drug Regimen on Pain in Patient Receiving Partial Hip Replacement:Randomized Prospective Study.

**NCT ID:** [NCT01112436](https://clinicaltrials.gov/study/NCT01112436)

## Key Facts

- **Status:** UNKNOWN
- **Phase:** PHASE4
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 258
- **Lead Sponsor:** Chung-Ang University Hosptial, Chung-Ang University College of Medicine
- **Conditions:** Femoral Neck Fracture
- **Start Date:** 2010-05
- **Completion Date:** 2012-04
- **CT.gov Last Update:** 2011-06-27

## Brief Summary

This prospective randomized study aims to evaluate the effectiveness of periarticular multi-drug regimen injection on the relief of pain in patients undergoing partial hip replacement.

Total 258 patients will be randomized into one of two groups (groupC or groupI) based on Excel number generation.

Patients in group C will receive no medication intraoperatively, and patients in group I will receive oral oxycodone and celecoxib preoperatively and a periarticular injection of multi-drug regimen during operation.

Visual analogue scale pain scores, fentanyl consumption and the frequency at which patients pushed the button (FPB) of a patient-controlled analgesia system will be recorded at 1, 4, 7 postoperative day.

## Detailed Description

Patients in group I will receive oxycodone SR 10 mg, and celecoxib 200 mg with 10 ml of water 1 hour before surgery.

And patients in group I will receive periarticular injection of 50 ml solution which contains ropivacaine 15 mg, epinephrine 0.3 mg, cefmetazole 1000mg, ketorolac 30 mg and morphine HCL 10mg before closure of surgical wound.

Patients in group C will receive no medication.

## Eligibility

- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* femoral neck fracture
* partial hip replacement

Exclusion Criteria:

* r/o infection
* reoperation
* mental change
```

## Arms

- **control group (group C)** (PLACEBO_COMPARATOR) — control group will receive no medication preoperatively and during operation
- **periarticular injecion group (group I)** (ACTIVE_COMPARATOR) — patients in Group I will receive oral oxycodone SR 10 mg and celecoxib 200 mg 1 hour preoperatively with sips of water, and receive periarticular injection of combination of ropivacaine 15 mg, morphine 10 mg, ketorolac 30 mg epinephrine 0.3 mg and cefmetazole 1000mg during operation.

## Interventions

- **periarticular injection of multidrug regimen** (DRUG) — periarticular injection of combination of ropivacaine 15 mg, epinephrine 0.3mg, cefmetazole 1000mg, ketorolac 30mg, morphine HCL 10 mg
- **none of medication preoperatively and intraoperatively** (DRUG) — Patients in Group C wil receive none of medication preoperatively and intraoperatively

## Primary Outcomes

- **Visual analogue scale 1day** _(time frame: Post Op 1 day)_ — Patients will be assessed for pain using a visual analogue pain scale (VAS). It is usually a horizontal line, 100 mm in length, anchored by word descriptors at each end; left side end which represents 0 is 'No pain', right side end with 100 is 'Very severe pain'. The patient marks on the line the point that they feel represents their perception of their current state. The VAS score is determined by measuring in millimeters from the left hand end of the line to the point that the patient marks.

To check the severity of pain VAS will be measured at post op 1day.

## Secondary Outcomes

- **Opioid consumption 1day** _(time frame: Post Op 1 day)_
- **FPB 1day** _(time frame: Post Op 1 day)_
- **delirium rating scale at admission** _(time frame: at admission)_
- **Visual Analogue Scale 4day** _(time frame: Post OP 4day)_
- **Visual Analogue Scale 7day** _(time frame: Post Op 7day)_
- **Opioid consumption 4day** _(time frame: Post Op 4 day)_
- **Opioid consumption 7day** _(time frame: Post Op 7 day)_
- **FPB 4day** _(time frame: Post Op 4 day)_
- **FPB 7day** _(time frame: Post Op 7 day)_
- **delirium rating scale 1day** _(time frame: Post Op 1day)_
- **delirium rating scale 4day** _(time frame: Post Op 4day)_
- **delirium rating scale 7day** _(time frame: Post Op 7day)_

## Locations (1)

- ChungAng University, Seoul, South Korea — _RECRUITING_

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.chungang university|seoul||south korea` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT01112436.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT01112436*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*